ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Evaluating PI-RADS lesions and clinically significant prostate cancer in Black and Asian men: a PREVENT randomized clinical trial secondary analysis.Prostate cancer and prostatic diseases · 2026Trial
- Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in European American and African American men.Journal of the National Cancer Institute · 2026Article
- Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).Clinical genitourinary cancer · 2026Article
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- The value of MRI-based radiomics and clinicoradiological data for the detection of forkhead box protein A1 gene mutated prostate cancer.Scientific reports · 2025Article
- Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment.Nature communications · 2024Article
- Differences in the mutational landscape of clonal hematopoiesis of indeterminate potential among races and between male and female patients with cancer.Experimental hematology · 2024Article
- Extrachromosomal circular DNA promotes prostate cancer progression through the FAM84B/CDKN1B/MYC/WWP1 axis.Cellular & molecular biology letters · 2024Article
- Comprehensive data mining reveals RTK/RAS signaling pathway as a promoter of prostate cancer lineage plasticity through transcription factors and CNV.Scientific reports · 2024Article
- Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis.Nature communications · 2024Article
- Article
- Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer.JCI insight · 2023Article
- Review
- Article
- Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- Review
- Cancer health disparities in racial/ethnic minorities in the United States.British journal of cancer · 2021Review
- FOXA1 in prostate cancer.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
purposeThe potential biological determinants of aggressive prostate cancer in African American (AA) men are unknown. Here we characterize prostate cancer genomic alterations in the largest cohort to date of AA men with clinical follow-up for metastasis, with the aim to elucidate the key molecular drivers associated with poor prognosis in this population. EXPERIMENTAL
designTargeted sequencing was retrospectively performed on 205 prostate tumors from AA men treated with radical prostatectomy (RP) to examine somatic genomic alterations and percent of the genome with copy-number alterations (PGA). Cox proportional hazards analyses assessed the association of genomic alterations with risk of metastasis.
resultsAt RP, 71% (145/205) of patients had grade group ≥3 disease, and 49% (99/202) were non-organ confined. The median PGA was 3.7% (IQR = 0.9%-9.4%) and differed by pathologic grade (
conclusionsOverall, PGA, somatic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.